-
-
-
Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Ruizhen Li, Xiaofen Li, Xin You, Minggang Su, Yuzhi Liu, Nengwen Ke, Dan Cao
BackgroundMore than half of neuroendocrine tumor (NET) patients will experience liver metastasis, and interventional therapy represented by transarterial embolization (TAE) is the main local treatment method. Surufatinib is recommended as a standard systemic treatment for advanced NETs. The efficacy and safety of surufatinib combined with TAE in the treatment of liver metastasis are undetermined. This
-
Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Ajami Gikandi, Susan N. Chi, Kee Kiat Yeo, Allison F. O'Neill, David S. Shulman, Steven G. DuBois, Natalie B. Collins
BackgroundImmune checkpoint inhibitors (ICI) have improved outcomes in a variety of adult cancers and are prescribed with increasing frequency across oncology. However, patterns of off‐label use of ICI in pediatrics remain unclear.MethodsThis is a single‐institution, retrospective cohort study evaluating off‐label ICI use in pediatric and young adult patients with cancer treated at our institution
-
Identifying predictors of COVID‐related delays in cancer‐specific medical care Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Breanna B. Greteman, Natalie J. Del Vecchio, Crystal J. Garcia‐Auguste, Amanda R. Kahl, Brian M. Gryzlak, Elizabeth A. Chrischilles, Mary E. Charlton, Sarah H. Nash
PurposeEvidence of the impact of the COVID‐19 pandemic on cancer prevention and control is growing, but little is known about patient‐level factors associated with delayed care. We analyzed data from a survey focused on Iowan cancer patients' COVID‐19 experiences in the early part of the pandemic.MethodsParticipants were recruited from the University of Iowa Holden Comprehensive Cancer Center's Patients
-
Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Shizhe Li, He Zhang, Ting Chen, Xiaowen Zhang, Guanning Shang
BackgroundThe proto‐oncogene ROS1 encodes an intrinsic type I membrane protein of the tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various malignancies via self‐mutations or rearrangements. Studies on ROS1‐directed tyrosine kinase inhibitors have been conducted, and some have been approved by the FDA for clinical use. However, the adverse effects and mechanisms of resistance
-
Understanding the financial cost of cancer clinical trial participation Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Courtney P. Williams, Luqin Deng, Nicole E. Caston, Kathleen Gallagher, Rebekah Angove, Maria Pisu, Andres Azuero, Rebecca Arend, Gabrielle B. Rocque
BackgroundThough financial hardship is a well‐documented adverse effect of standard‐of‐care cancer treatment, little is known about out‐of‐pocket costs and their impact on patients participating in cancer clinical trials. This study explored the financial effects of cancer clinical trial participation.MethodsThis cross‐sectional analysis used survey data collected in December 2022 and May 2023 from
-
Outcomes of the transformation of follicular lymphoma to diffuse large B‐cell lymphoma in the rituximab era: A population‐based study Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Wenshuai Zheng, Mingjuan Liu, Lixun Guan, Shenyu Wang
BackgroundHistological transformation (HT) to diffuse large B‐cell lymphoma (DLBCL) is a common complication of follicular lymphoma (FL) and is usually associated with a dismal outcome. However, the survival rate of these patients has improved over the last 20 years with the introduction of rituximab. This study aimed to access the outcome of transformation to DLBCL (t‐DLBCL) from FL in a retrospective
-
Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N. D'Alessandro‐Gabazza, Esteban C. Gabazza, Tetsu Kobayashi
BackgroundImmune checkpoint inhibitors have recently become the standard of care in the first‐line treatment of extensive‐stage small cell lung cancer. Although immune‐related adverse events have been reported to influence prognosis in non‐small cell lung cancer patients, few studies have investigated the prognostic value of immune‐related adverse events in small cell lung cancer patients. In this
-
Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study Cancer Med. (IF 4.0) Pub Date : 2024-04-16 Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
ObjectiveKINDLE‐Korea is part of a real‐world KINDLE study that aimed to characterize the treatment patterns and clinical outcomes of patients with stage III non‐small cell lung cancer (NSCLC).Materials and MethodsThe KINDLE was an international real‐world study that explores patient and disease characteristics, treatment patterns, and survival outcomes. The KINDLE‐Korea included stage III NSCLC patients
-
Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR Cancer Med. (IF 4.0) Pub Date : 2024-04-15 Zhanlong Wang, Xin Tian, Jinyu Ma, Yuhui Zhang, Wenru Ta, Yifan Duan, Fengli Li, Hong Zhang, Long Chen, Shaobin Yang, Enbin Liu, Yani Lin, Weiping Yuan, Kun Ru, Jie Bai
-
The RNA‐binding protein RBMS3 inhibits the progression of colon cancer by regulating the stability of LIMS1 mRNA Cancer Med. (IF 4.0) Pub Date : 2024-04-15 Yafei Li, Shuoshuo Wang, Guoli Li, Chunyang Gao, Zihan Cui, Mingqi Cong, Jie Hu, Minghui Zhang, Xiaoming Jin, Haiying Sun, Dan Kong
-
Application of interpretable machine learning algorithms to predict distant metastasis in ovarian clear cell carcinoma Cancer Med. (IF 4.0) Pub Date : 2024-04-13 Qin‐Hua Guo, Feng‐Chun Xie, Fang‐Min Zhong, Wen Wen, Xue‐Ru Zhang, Xia‐Jing Yu, Xin‐Lu Wang, Bo Huang, Li‐Ping Li, Xiao‐Zhong Wang
BackgroundOvarian clear cell carcinoma (OCCC) represents a subtype of ovarian epithelial carcinoma (OEC) known for its limited responsiveness to chemotherapy, and the onset of distant metastasis significantly impacts patient prognoses. This study aimed to identify potential risk factors contributing to the occurrence of distant metastasis in OCCC.MethodsUtilizing the Surveillance, Epidemiology, and
-
The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression Cancer Med. (IF 4.0) Pub Date : 2024-04-13 Qi Wang, Yuxi Huang, Yu Zhu, Wenlong Zhang, Binfeng Wang, Xuefeng Du, Qiqiang Dai, Fabiao Zhang, Zheping Fang
-
PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence Cancer Med. (IF 4.0) Pub Date : 2024-04-13 Litang Huang, Shen Chen, Hui Liu, Lu Meng, Chengxing Liu, Xiaoting Wu, Yingying Wang, Shilan Luo, Hongbin Tu, Chunlei Wang, Ming Zhang, Xiaomei Gong
BackgroundNumerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SCLC‐BMs).MethodsWe conducted a retrospective study by analyzing medical records of patients with SCLC‐BMs from January
-
Expression and prognostic significance of the PD‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma Cancer Med. (IF 4.0) Pub Date : 2024-04-13 Han Zhao, Shaohang Cai, Yanhua Xiao, Muye Xia, Hongjie Chen, Zhiman Xie, Xiaoping Tang, Haolan He, Jie Peng, Juanjuan Chen
ObjectiveImmune tolerance and evasion play a critical role in virus‐driven malignancies. However, the phenotype and clinical significance of programmed cell death 1 (PD‐1) and its ligands, PD‐L1 and PD‐L2, in aggressive acquired immunodeficiency syndrome (AIDS)‐related non‐Hodgkin lymphoma (AR‐NHL) remain poorly understood, particularly in the Epstein–Barr virus (EBV)‐positive subset.MethodsWe used
-
Outcomes after fertility‐sparing surgery of early‐stage ovarian cancer: A nationwide population‐based study Cancer Med. (IF 4.0) Pub Date : 2024-04-12 Chia‐Yi Lee, Chun‐Ju Chiang, Yi‐Jou Tai, Heng‐Cheng Hsu, Yu‐Li Chen, Ying‐Cheng Chiang, Chia‐Ying Wu, Wen‐Chung Lee, Hsiao‐Lin Hwa, Wen‐Fang Cheng
-
Chidamide plus envafolimab as subsequent treatment in advanced non‐small cell lung cancer patients resistant to anti‐PD‐1 therapy: A multicohort, open‐label, phase II trial with biomarker analysis Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Yaxiong Zhang, Zihong Chen, Yu Liu, Liang Han, Wei Jiang, Qiming Wang, Jianhua Shi, Liqin Lu, Jianying Li, Mingjun Zhang, Yan Huang, Yunpeng Yang, Xue Hou, Li Zhang, Jing Li, Wenfeng Fang, Gang Chen
BackgroundCombination of chidamide and anti‐PD‐L1 inhibitor produce synergistic anti‐tumor effect in advanced NSCLC patients resistant to anti‐PD‐1 treatment. However, the effect of chidamide plus envafolimab has not been reported.AimsThis study aimed to evaluate the efficacy of chidamide plus envafolimab in advanced NSCLC patients resistant toanti‐PD‐1 treatment.Materials and MethodsEligible advanced
-
Bayesian and deep‐learning models applied to the early detection of ovarian cancer using multiple longitudinal biomarkers Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Luis Abrego, Alexey Zaikin, Ines P. Marino, Mikhail I. Krivonosov, Ian Jacobs, Usha Menon, Aleksandra Gentry‐Maharaj, Oleg Blyuss
-
What is the relationship between the local population change and cancer incidence in patients with dyslipidemia: Evidence of the impact of local extinction in Korea Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Wonjeong Jeong, Dong‐Woo Choi, Woorim Kim, Kyu‐Tae Han
BackgroundChanges in the local population are intricately linked to healthcare infrastructure, which subsequently impacts the healthcare sector. A decreasing local population can result in lagging health infrastructure, potentially leading to adverse health outcomes as patients may be at risk of not receiving optimal care and treatment. While some studies have explored the relationship between chronic
-
Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Helmneh M. Sineshaw, Christina M. Zettler, Jennifer Prescott, Mahek Garg, Samhita Chakraborty, Eric M. Sarpong, Claire Bai, Andrew J. Belli, Laura L. Fernandes, Ching‐Kun Wang
-
Novel definition of textbook outcome in biliary system cancers and its influence on patients' survival and quality of life Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Manar Mikhail Atyah, Li Xu, Zhiying Yang
BackgroundThe definition of textbook outcome in biliary system cancers is a developing concept in need of expansion and investigation of its association with survival and quality of life.MethodsIn this original research, we developed a novel “all or none” textbook outcome definition which addresses the rapid recovery of post‐surgical indexes, in addition to short‐term mortality, hospital re‐admission
-
The impact of the affordable care act and Medicaid expansion on colorectal cancer screening: Evidence from the 5th year of Medicaid expansion Cancer Med. (IF 4.0) Pub Date : 2024-04-09 Michael A. Preston, Mahmoud Manouchehri Amoli, Askar S. Chukmaitov, Alex H. Krist, Bassam Dahman
-
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID) Cancer Med. (IF 4.0) Pub Date : 2024-04-09 Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D. Danenberg, Narikazu Boku, Takako Eguchi Nakajima
BackgroundLong‐term anti‐EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single‐arm, phase II trial aimed to investigate the strategy of switching from cetuximab to bevacizumab in combination with FOLFIRI based on early tumor shrinkage (ETS) in patients with RAS wild‐type metastatic colorectal cancer (mCRC).MethodsRadiologic assessment was performed to evaluate ETS
-
Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy Cancer Med. (IF 4.0) Pub Date : 2024-04-09 Dongchan Kim, Sheehyun Kim, Hyojin Song, Daehyeon Gwak, Suji Min, Ja Min Byun, Youngil Koh, Junshik Hong, Sung‐Soo Yoon, Hongseok Yun, Dong‐Yeop Shin
BackgroundAcute myeloid leukemia (AML) is characterized by clonal heterogeneity, leading to frequent relapses and drug resistance despite intensive clinical therapy. Although AML's clonal architecture has been addressed in many studies, practical monitoring of dynamic changes in those subclones during relapse and treatment is still understudied.MethodFifteen longitudinal bone marrow (BM) samples were
-
Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation Cancer Med. (IF 4.0) Pub Date : 2024-04-06 Alisha R. Pershad, Punam G. Thakkar, Joseph F. Goodman, Arjun Joshi, Seth M. Steinberg, Clint T. Allen, Charalampos S. Floudas
-
RSPO3 induced by Helicobacter pylori extracts promotes gastric cancer stem cell properties through the GNG7/β‐catenin signaling pathway Cancer Med. (IF 4.0) Pub Date : 2024-04-06 Xiwu Rao, Zhipeng Zhang, Yunzhou Pu, Gang Han, Hangjun Gong, Hao Hu, Qing Ji, Ningning Liu
BackgroundHelicobacter pylori (H. pylori) accounts for the majority of gastric cancer (GC) cases globally. The present study found that H. pylori promoted GC stem cell (CSC)‐like properties, therefore, the regulatory mechanism of how H. pylori promotes GC stemness was explored.MethodsSpheroid‐formation experiments were performed to explore the self‐renewal capacity of GC cells. The expression of R‐spondin
-
Artificial intelligence in lung cancer screening: Detection, classification, prediction, and prognosis Cancer Med. (IF 4.0) Pub Date : 2024-04-06 Wu Quanyang, Huang Yao, Wang Sicong, Qi Linlin, Zhang Zewei, Hou Donghui, Li Hongjia, Zhao Shijun
BackgroundThe exceptional capabilities of artificial intelligence (AI) in extracting image information and processing complex models have led to its recognition across various medical fields. With the continuous evolution of AI technologies based on deep learning, particularly the advent of convolutional neural networks (CNNs), AI presents an expanded horizon of applications in lung cancer screening
-
The inverted U‐shaped relationship between epinephrine and pancreatic ductal adenocarcinoma patients' survival with compensation of lymphocyte Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Bing‐Xue Li, Xiao‐Cen Zhu, Xia‐Xing Deng
-
Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Ryosuke Uekusa, Akira Yokoi, Eri Watanabe, Kosuke Yoshida, Masato Yoshihara, Satoshi Tamauchi, Yusuke Shimizu, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama
BackgroundPoly (ADP‐ribose) polymerase (PARP) inhibitors have been increasingly used in the treatment of ovarian cancer, with BRCA positivity and homologous recombination deficiency (HRD) being common biomarkers used for predicting their efficacy. However, given the limitations of these biomarkers, new ones need to be explored.MethodsThis retrospective study included 181 ovarian cancer patients who
-
Household income and health‐related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Haley Newman, Yimei Li, Yuan‐Shung V. Huang, Caitlin W. Elgarten, Regina M. Myers, Jenny Ruiz, Daniel J. Zheng, Alison Barz Leahy, Catherine Aftandilian, Staci D. Arnold, Kira Bona, M. Monica Gramatges, Mallorie B. Heneghan, Kelly W. Maloney, Arunkumar J. Modi, Rajen J. Mody, Elaine Morgan, Jeffrey Rubnitz, Naomi Winick, Jennifer J. Wilkes, Alix E. Seif, Brian T. Fisher, Richard Aplenc, Kelly D. Getz
ObjectiveExamine the influence of household income on health‐related quality of life (HRQOL) among children with newly diagnosed acute myeloid leukemia (AML).DesignSecondary analysis of data prospectively collected from pediatric patients receiving treatment for AML at 14 hospitals across the United States.ExposureHousehold income was self‐reported on a demographic survey. The examined mediators included
-
Treatment outcome and germline predictive factors of ropeginterferon alpha‐2b in myeloproliferative neoplasm patients Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Chih‐Cheng Chen, Ming‐Chung Kuo, Ying‐Hsuan Wang, Sung‐Nan Pei, Ming‐Lih Huang, Chiu‐Chen Chen, Cih‐En Huang, Yi‐Yang Chen, Lee‐Yung Shih
-
Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Linlin Zheng, Yaru Wang, Zhenrong Liu, Zhihao Wang, Changcheng Tao, Anke Wu, Haiyang Li, Ting Xiao, Zhuo Li, Weiqi Rong
-
Changes in rural caregivers' health behaviors while supporting someone with cancer: A qualitative study Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Elizabeth A. Johnston, Katelyn E. Collins, Jazmin N. Vicario, Chris Sibthorpe, Michael J. Ireland, Belinda C. Goodwin
-
Trends in breast, colon, pancreatic, and uterine cancers in women during the COVID‐19 pandemic in North Carolina Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Sarah J. Nyante, Allison M. Deal, Hillary M. Heiling, Kyung Su Kim, Cherie M. Kuzmiak, Benjamin C. Calhoun, Emily M. Ray
-
Comparison between next‐generation sequencing and multiplex polymerase chain reaction assays for nonsmall‐cell lung cancer molecular diagnosis Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Shuji Murakami, Kanako Shinada, Yuka Otsutsumi, Fumiko Komine, Yuan Yuan, Junko Nakamura, Seigo Katakura, Tetsuro Kondo, Terufumi Kato, Tomoyuki Yokose, Haruhiro Saito
-
A population study comparing tracheal and lung adenoid cystic carcinoma Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Yu Gu, Songtao Lai, Yang Wang, Juan Yang, Ping Zhou, Tianxiang Chen
BackgroundThoracic adenoid cystic carcinoma (ACC) is rare, and the differences between tracheal and lung lesions have not been fully understood.MethodsPatients were identified from a Chinese cancer center (FUSCC) (2005–2022) and the Surveillance, Epidemiology, and End Results (SEER) database (2000–2019). Incidence was calculated and trends were quantified. Clinicopathological features and overall survival
-
Developing and validating a nomogram for penile cancer survival: A comprehensive study based on SEER and Chinese data Cancer Med. (IF 4.0) Pub Date : 2024-04-03 Jiawen Luo, Jintao Hu, Yelisudan Mulati, Zhikai Wu, Cong Lai, Degeng Kong, Cheng Liu, Kewei Xu
ObjectiveThe primary aim of this study was to create a nomogram for predicting survival outcomes in penile cancer patients, utilizing data from the Surveillance, Epidemiology, and End Results (SEER) and a Chinese organization.MethodsOur study involved a cohort of 5744 patients diagnosed with penile cancer from the SEER database, spanning from 2004 to 2019. In addition, 103 patients with penile cancer
-
Metformin suppresses NFE2L1 pathway activation to inhibit gap junction beta protein expression in NSCLC Cancer Med. (IF 4.0) Pub Date : 2024-04-02 Shuo Yu, Hui Ren, Tingting Liu, Xiaoyan Han, Hui Guo, Qian Ning, Yang Li, Hong Zhou, Mingwei Chen, Tinghua Hu
ObjectiveNon‐small‐cell lung cancer (NSCLC) is a deadly form of cancer that exhibits extensive intercellular communication which contributed to chemoradiotherapy resistance. Recent evidence suggests that arrange of key proteins are involved in lung cancer progression, including gap junction proteins (GJPs).Methods and ResultsIn this study, we examined the expression patterns of GJPs in NSCLC, uncovering
-
Association between novel genetic variants of Notch signaling pathway genes and survival of hepatitis B virus‐related hepatocellular carcinoma Cancer Med. (IF 4.0) Pub Date : 2024-04-02 Liming Qin, Moqin Qiu, Qiuling Lin, Binbin Jiang, Shicheng Zhan, Xueyan Wei, Junjie Wei, Yingchun Liu, Qiuping Wen, Peiqin Chen, Yanji Jiang, Zihan Zhou, Xiumei Liang, Ji Cao, Yizhen Gong, Yuying Wei, Xiaoxia Wei, Hongping Yu
-
Analysis of related factors of CRA in lung cancer patients with different serum iron levels: A retrospective cohort study Cancer Med. (IF 4.0) Pub Date : 2024-04-02 Quan‐yao Li, Wen‐xiao Yang, Hui Liu, Jia‐lin Yao, Qin Wang, Dan Lin, Jun Shi
BackgroundSerum iron, an essential component of hemoglobin (Hb) synthesis in vivo, is a crucial parameter for evaluating the body's iron storage and metabolism capacity. Iron deficiency leads to reduced Hb synthesis in red blood cells and smaller red blood cell volume, ultimately resulting in iron‐deficiency anemia. Although serum iron cannot independently evaluate iron storage or metabolism ability
-
Correction to “Dose‐dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin‐like growth factor‐1” Cancer Med. (IF 4.0) Pub Date : 2024-04-02
Leticia M. Nogueira, Jackie A. Lavigne, Gadisetti V. R. Chandramouli, Huaitian Lui, J. Carl Barrett, Stephen D. Hursting. Dose-dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin-like growth factor-1. Cancer Med. 2012; 1:275–288. doi: 10.1002/cam4.23 The typo in the co-author name has been corrected. The corrected co-author
-
Correction to “urban relatives ameliorate survival disparities for genitourinary cancer in rural patients” Cancer Med. (IF 4.0) Pub Date : 2024-04-02
Choudry M, Dindinger-Hill K, Ambrose J, et al. Urban relatives ameliorate survival disparities for genitourinary cancer in rural patients. Cancer Med. 2024;13:e7058. https://doi.org/10.1002/cam4.7058. The revised co-author name which is shown below has been added to the online version of the article. Trevor C. Hunt.
-
Tumor analysis of MMR genes in Lynch‐like syndrome: Challenges associated with results interpretation Cancer Med. (IF 4.0) Pub Date : 2024-04-01 Paula Rofes, Núria Dueñas, Jesús del Valle, Matilde Navarro, Judith Balmaña, Teresa Ramón y Cajal, Noemí Tuset, Carmen Castillo, Sara González, Joan Brunet, Gabriel Capellá, Conxi Lázaro, Marta Pineda
-
Characterization and impact of non‐canonical WNT signaling on outcomes of urothelial carcinoma Cancer Med. (IF 4.0) Pub Date : 2024-04-01 Margaret Meagher, Harris Krause, Andrew Elliott, Alex Farrell, Emmanuel S. Antonarakis, Bruno Bastos, Elisabeth I. Heath, Christina Jamieson, Tyler F. Stewart, Aditya Bagrodia, Chadi Nabhan, Matt Oberley, Rana R. McKay, Amirali Salmasi
BackgroundNon‐canonical WNT family (WNT5A pathway) signaling via WNT5A through ROR1 and its partner, ROR2, or Frizzled2 (FZD2) is linked to processes driving tumorigenesis and therapy resistance. We utilized a large dataset of urothelial carcinoma (UC) tumors to characterize non‐canonical WNT signaling through WNT5A, ROR1, ROR2, or FZD2 expression.MethodsNextGen Sequencing of DNA (592 genes or WES)/RNA
-
A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience Cancer Med. (IF 4.0) Pub Date : 2024-04-01 Anna Furlan, Michele Cea, Laura Pavan, Monica Galli, Cristina Clissa, Silvia Mangiacavalli, Anna Maria Cafro, Stefania Girlanda, Francesca Patriarca, Claudia Minotto, Giovanni Bertoldero, Gregorio Barilà, Anna Pascarella, Albana Lico, Rossella Paolini, Nicholas Rabassi, Norbert Pescosta, Marika Porrazzo, Giovanni De Sabbata, Alessandra Pompa, Giulia Bega, Stefania Cavallin, Francesca Guidotti, Magda
IntroductionIxazomib, lenalidomide, and dexamethasone (IRd) have been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the TOURMALINE‐MM1.Objectives and MethodsWe conducted a retrospective–prospective analysis of 106 RRMM patients (pts) treated with IRd in 21 centers in Northern Italy, with the aim to evaluate the efficacy and safety of IRd in real life
-
Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis Cancer Med. (IF 4.0) Pub Date : 2024-03-30 Shoutao Dang, Xinyu Li, Heshu Liu, Shuyang Zhang, Wei Li
BackgroundImmune checkpoint inhibitors (ICIs) are widely used in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC); however, the toxicity profiles are inconclusive.MethodsClinical trials evaluating ICIs for R/M HNSCC were searched from online databases. The characteristics of the studies and the results of incidences of any grade treatment‐related adverse events (trAEs), grade
-
Association of household net worth with healthcare costs after radical cystectomy using real‐world data Cancer Med. (IF 4.0) Pub Date : 2024-03-30 Samuel L. Washington, Peter E. Lonergan, Anobel Y. Odisho, Maxwell V. Meng, Sima P. Porten
BackgroundFinancial toxicity of bladder cancer care may influence how patients utilize healthcare resources, from emergency department (ED) encounters to office visits. We aim to examine whether greater household net worth (HHNW) confers differential access to healthcare resources after radical cystectomy (RC).MethodsThis population‐based cohort study examined the association between HHNW and healthcare
-
Similar immune responses to alpha1‐oleate and Bacillus Calmette–Guérin treatment in patients with bladder cancer Cancer Med. (IF 4.0) Pub Date : 2024-03-30 Shahram Ahmadi, Ines Ambite, Antonín Brisuda, Jaromír Háček, Farhan Haq, Samudra Sabari, Kamala Vanarsa, Chandra Mohan, Marek Babjuk, Catharina Svanborg
BackgroundThe molecular content of urine is defined by filtration in the kidneys and by local release from tissues lining the urinary tract. Pathological processes and different therapies change the molecular composition of urine and a variety of markers have been analyzed in patients with bladder cancer. The response to BCG immunotherapy and chemotherapy has been extensively studied and elevated urine
-
Added value of whole‐exome and RNA sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel Cancer Med. (IF 4.0) Pub Date : 2024-03-30 Armelle Dufresne, Valéry Attignon, Anthony Ferrari, Laurie Tonon, Sandrine Boyault, Séverine Tabone‐Eglinger, Philippe Cassier, Olivier Trédan, Nadège Corradini, Armelle Vinceneux, Aurélie Swalduz, Alain Viari, Sylvie Chabaud, David Pérol, Jean Yves Blay, Pierre Saintigny
IntroductionThe objective was to determine the added value of comprehensive molecular profile by whole‐exome and RNA sequencing (WES/RNA‐Seq) in advanced and refractory cancer patients who had no molecular‐based treatment recommendation (MBTR) based on a more limited targeted gene panel (TGP) plus array‐based comparative genomic hybridization (aCGH).Materials and MethodsIn this retrospective analysis
-
Prognostic significance of systemic immune‐inflammation index in patients with nonfunction pancreatic neuroendocrine tumor undergoing surgical resection Cancer Med. (IF 4.0) Pub Date : 2024-03-30 Guanhua Chen, Li Liu, Chunlu Tan, Qingquan Tan, Yonghua Chen, Xiangrong An, Xubao Liu, Xing Wang
PurposeThe purpose of our study was to investigate the clinical significance and prognostic role of the systemic immune‐inflammation index (SII) in patients who underwent surgical resection for nonfunctioning pancreatic neuroendocrine tumors (pNETs).MethodsWe conducted a retrospective analysis of 364 patients with nonfunctioning pNETs. The association between the SII level and clinical parameters was
-
The quantitative parameters based on marrow metabolism derived from synthetic MRI: A pilot study of prognostic value in participants with newly diagnosed multiple myeloma Cancer Med. (IF 4.0) Pub Date : 2024-03-30 Sha Cui, Yinnan Guo, Weiran Niu, Jianting Li, Wenjin Bian, Wenqi Wu, Wenjia Zhang, Qian Zheng, Jun Wang, Jinliang Niu
BackgroundThe value of SyMRI‐derived parameters from lumbar marrow for predicting early treatment response and optimizing the risk stratification of the Revised International Staging System (R‐ISS) in participants with multiple myeloma (MM) is unknown.MethodsWe prospectively enrolled participants with newly diagnosed MM before treatment. The SyMRI of lumbar marrow was used to calculate T1, T2, and
-
Relationship between educational level and survival of patients with cancer: A multicentre cohort study Cancer Med. (IF 4.0) Pub Date : 2024-03-28 Xiao-Yue Liu, Xi Zhang, Guo-Tian Ruan, Xin Zheng, Yue Chen, Xiao-Wei Zhang, Tong Liu, Yi-Zhong Ge, Han-Ping Shi
Although socioeconomic factors are important determinants of population mortality, the effect of educational level on the survival of patients with cancer in China is unclear. This study aimed to assess whether educational level is associated with the prognosis of patients with cancer and to explore the mediators of this association.
-
Patterns of follow‐up care in adult blood cancer survivors—Prospective evaluation of health‐related outcomes, resource use, and quality of life Cancer Med. (IF 4.0) Pub Date : 2024-03-29 Hildegard Lax, Julia Baum, Nils Lehmann, Anja Merkel‐Jens, Dietrich W. Beelen, Karl‐Heinz Jöckel, Ulrich Dührsen
BackgroundInformation about follow‐up care in blood cancer survivors is limited. The questionnaire‐based “Aftercare in Blood Cancer Survivors” (ABC) study aimed to identify patterns of follow‐up care in Germany and compare different types of follow‐up institutions.MethodsThe study's 18‐month prospective part compared the follow‐up institutions identified in the preceding retrospective part (academic
-
Standardized uptake valuemax of the primary lesion combined with tumor markers for clinically predicting distant metastasis in de novo lung adenocarcinoma Cancer Med. (IF 4.0) Pub Date : 2024-03-29 Baoli Jin, Xiaolian Wen, Hanji Tian, Hongxia Guo, Mingyan Hao, Jing Wu, Xiaomin Li, Yuejun Ren, Xin Wang, Xiaolu Ren
BackgroundTo examine standardized uptake valuemax of the primary lesion (pSUVmax) and tumor markers (TMs) for clinically predicting distant metastasis in novo lung adenocarcinoma.MethodsThe current retrospective observational study examined individuals diagnosed with de novo lung adenocarcinoma at Shanxi Cancer Hospital between February 2015 and December 2019.ResultsTotally, 532 de novo lung adenocarcinoma
-
Development and internal validation of a nomogram based on peripheral blood inflammatory markers for predicting prognosis in nasopharyngeal carcinoma Cancer Med. (IF 4.0) Pub Date : 2024-03-29 Jing Lai, Peixin Lin, Jiafeng Zhuang, Zhiwei Xie, Hechao Zhou, Donghong Yang, Zihong Chen, Danxian Jiang, Jing Huang
BackgroundInflammatory markers, including the product of neutrophil count, platelet count, and monocyte count divided by lymphocyte count (PIV) and the platelet‐to‐white blood cell ratio (PWR), have not been previously reported as prognostic factors in nasopharyngeal carcinoma (NPC) patients. In order to predict overall survival (OS) in NPC patients, our goal was to create and internally evaluate a
-
Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy Cancer Med. (IF 4.0) Pub Date : 2024-03-29 Wei‐Chun Chen, Wen‐Chien Cheng, Chieh‐Lung Chen, Wei‐Chih Liao, Chia‐Hung Chen, Hung‐Jen Chen, Chih‐Yen Tu, Chi‐Chen Lin, Te‐Chun Hsia
BackgroundThis study aimed to examine the clinical characteristics of bone metastasis (BoM) in patients with non‐small cell lung cancer (NSCLC) who have an epidermal growth factor receptor (EGFR) mutation and to identify the most effective treatment strategy using EGFR–tyrosine kinase inhibitors (TKIs).MethodsThe study included patients with stage IV EGFR‐mutated NSCLC who were receiving first‐line
-
Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy Cancer Med. (IF 4.0) Pub Date : 2024-03-28 Angel Guan, Justin J.‐L. Wong
-
Early detection of nasopharyngeal carcinoma through machine‐learning‐driven prediction model in a population‐based healthcare record database Cancer Med. (IF 4.0) Pub Date : 2024-03-28 Jeng‐Wen Chen, Shih‐Tsang Lin, Yi‐Chun Lin, Bo‐Sian Wang, Yu‐Ning Chien, Hung‐Yi Chiou
-
Trauma plays an important role in acral melanoma: A retrospective study of 303 patients Cancer Med. (IF 4.0) Pub Date : 2024-03-28 Rong Huang, Mengke Zhao, Guiying Zhang, Yueling Yang, Jiayu Wang, Kelin Zheng, Lin Li, Xinyu Su, Lianjun Zhao, Yirong Wu, Zhengyun Zou